Skip to content

NeuroSense Therapeutics Ltd.

NRSN· NasdaqCore metricsCIK 1875091

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · +4.65%
Market cap
$58.60M
32.56M shares
Filings
314
—
—
—
-$11.13M
FY 2025N/M FY25 yoy
-$11.09M
FY 2025N/M FY25 yoy
-$7.68M
FY 2025derivedN/M FY25 yoy
-$0.44
FY 2025N/M FY25 yoy
$166.00K
FY 2025−95.1% FY25 yoy
$58.60M
—
—
—
-13.10%
—

FY2025 figures · derived

Price

$1.80+87.48%+$0.84past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Gross Profit

$7.00KQ2 2023
No annual history for this metric yet.
PeriodEndedValueKindSource trail

Capital returns

Dividends and buybacks · FY2019 to FY2023
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2023$310.00K—$310.00K—15.38M sh——
FY2022$310.00K—$310.00K————
FY2021$29.00K—$29.00K—10.94M sh——
FY2020$28.00K—$28.00K————
FY2019$27.00K—$27.00K————

Pharmaceutical preparations

NeuroSense Therapeutics Ltd. is the 323rd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

NeuroSense Therapeutics Ltd. · CIK 1875091 · Engraved from SEC EDGAR